Summary: Transvascular gene therapy of Parkinson's disease (PD) is a new approach to the gene therapy of PD and involves the global distribution of a therapeutic gene to brain after an intravenous administration and transport across the blood-brain barrier (BBB). This is enabled with the development of a nonviral gene transfer technology that encapsulates plasmid DNA inside pegylated immunoliposomes or PILs. An 85-to 100-nm liposome carries the DNA inside the nanocontainer, and the liposome surface is conjugated with several thousand strands of 2000-Da polyethyleneglycol (PEG). This PEGylation of the liposome stabilizes the structure in the blood stream. The liposome is targeted across the BBB via attachment to the tips of 1-2% of the PEG strands of a receptor-specific monoclonal antibody (mAb) directed at a BBB receptor, such as the insulin receptor or transferrin receptor (TfR). Owing to the expression of the insulin receptor or the TfR on both the BBB and the neuronal plasma membrane, the PIL is able to reach the neuronal nuclear compartment from the circulation. Brain-specific expression is possible with the combined use of the PIL gene transfer technology and brain-specific gene promoters. In the 6-hydroxydopamine rat model of experimental PD, striatal tyrosine hydroxylase (TH) activity is completely normalized after an intravenous administration of TfRmAb-targeted PILs carrying a TH expression plasmid. A treatment for PD may be possible with dual gene therapy that seeks both to replace striatal TH gene expression with TH gene therapy, and to halt or reverse neurodegeneration of the nigro-striatal tract with neurotrophin gene therapy.
INTRODUCTION
Parkinson's disease (PD) affects nearly 1% of the U.S. population over 65 years and nearly 1 million individuals in the U.S. 1 The neurodegneration of the nigral-striatal tract results in a loss of dopaminergic neurons in the substantia-nigra, a loss of tyrosine hydroxylase containing nerve endings in the striatum, and diminished striatal dopamine production causing abnormal motor behavior. 2 Dopamine replacement therapy with dopamine is not possible in PD because this monoamine does not cross the brain capillary endothelial wall, which forms the blood-brain barrier (BBB) in vivo. However, the precursor to dopamine, L-dihydroxyphenylalanine (L-DOPA), does cross the BBB owing to transport via the BBB large neutral amino acid transporter, which is expressed by the LAT1 gene. 3 After its transport across the BBB, L-DOPA is decarboxylated to dopamine by aromatic amino acid decarboxylase (AAAD). The rate-limiting step in cerebral production of dopamine is normally the conversion of tyrosine to L-DOPA via tyrosine hydroxylase (TH).
L-DOPA replacement therapy has been the mainstay of Parkinson's treatment for 40 years. However, L-DOPA therapy is not without complications. Owing to ubiquitous expression of both AAAD in brain and LAT1 at the BBB, circulating L-DOPA is converted to dopamine throughout all parts of the brain including the striatum. Dopamine is an inhibitory neurotransmitter, and the ectopic production throughout the brain has side effects. An alternative approach to dopamine replacement therapy in PD is TH gene therapy, wherein an exogenous TH gene is expressed only in the circumscribed regions of the brain forming the dopaminergic nerve tracts.
OVERVIEW OF GENE THERAPY IN PARKINSON'S DISEASE
There are dual goals of gene therapy in PD: 1) replace striatal TH and 2) halt or even reverse the neurodegeneration of nigral-striatal neurons. The latter can be accomplished with local expression of neuroprotective neurotrophins such as glial-derived neurotrophic factor (GDNF). 4 The current approach to gene therapy of PD, and gene therapy of brain disorders in general, is the combined use of craniotomy as a delivery system, and viral vectors as a gene expression system. The transcranial injection of viral gene therapy vectors is clearly effective, including primate models, and allows for the local production of therapeutic genes. 4 The single injection into the human or animal brain of either adenovirus or herpes simplex virus results in inflammatory reaction leading to astrogliosis and demyelination, 5, 6 and more recent viral gene therapy approaches employ either adeno-associated virus (AAV) or retrovirus. AAV vectors generally need to be given at some repeat intervals, and 90% of the human population has a pre-existing immunity to AAV. 7 Both AAV and retrovirus permanently and randomly integrate into the host genome. 8, 9 Neither AAV nor retrovirus crosses the BBB. Therefore, it is necessary to administer the virus via craniotomy and an intracerebral injection. However, the most intense expression of the therapeutic gene is generally limited to the injection site, owing to limited diffusion of the virus within the brain. The treatment volume can be increased with convection-enhanced diffusion (CED). However, a recent study of CED in the primate brain shows an astrogliotic reaction over the entire region of the primate brain that is perfused during the CED procedure. 10 Current limitations of brain gene therapy approaches can be eliminated with the development of a transvascular delivery approach to gene therapy. However, this would require the formulation of plasmid DNA in such a way that the exogenous gene was able to cross the BBB and enter brain via the transvascular route after an intravenous injection. This is now possible with the use of a pegylated immunoliposomes that target genes across the BBB with receptor-specific molecular Trojan horses.
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PEGYLATED IMMUNOLIPOSOMES-A NEW APPROACH TO TRANSVASCULAR GENE THERAPY OF THE BRAIN
Exogenous genes incorporated in plasmid DNA can be widely distributed throughout the entire brain after an intravenous injection with the use of a new form of transvascular gene transfer technology that uses pegylated immunoliposomes, or PILs. The plasmid DNA is encapsulated in the interior of a 100-nm liposome. 12 The surface of the liposome is decorated with several thousand strands of 2000-Da polyethyleneglycol (PEG), and this pegylation process alters the surface of the liposome such that the liposome is not rapidly cleared by the reticulo-endothelial system after an intravenous administration. The pegylated liposome is relatively inert and does not cross the BBB. 13 However, transvascular transport of the PIL can be induced by conjugating receptor specific monoclonal antibodies (mAbs) to the tips of 1-2% of the PEG tails so that each 100-nm liposome is conjugated with approximately 50 mAb molecules. 12, 13 A drawing of a PIL is shown in Figure 1A . An actual PIL is visualized with electron microscopy as shown in Figure 1B . In this study, a conjugate of 10 nm gold and a secondary antibody was attached to the surface of the PIL to demonstrate the relationship of the targeting mAb to the surface of the PIL. 14 The size of a 10-nm gold particle is approximately the size of the targeting mAb, as depicted in Figure 1B . The plasmid DNA is encapsulated in the interior of the liposome, which renders the DNA insensitive to the ubiquitous exo-and endonucleases in the circulation. 12 The PIL is to be contrasted with conventional cationic liposomes that are a mixture of anionic DNA and a cationic polymer. Cationic liposome/DNA complexes are unstable in blood, aggregate in a saline environment, and are more than 99% cleared by the pulmonary circulation after a single intravenous injection. 15, 16 Cationic liposomes do not distribute to the brain after an intravenous administration. 17 PILs act as an artificial virus in that the PILs are approximately the same size as a virus, the DNA is contained inside the nanocontainer, and the surface of the nanocontainer has proteins that trigger uptake across membrane barriers. The targeting component of the PIL is a receptor-specific mAb that is conjugated to the tips of 1-2% of the PEG strands on the liposome surface. 12 The transferrin receptor (TfR) or the insulin receptor are expressed at both the BBB and on neuronal cell membranes. Therefore, a PIL, targeted with a mAb to either the TfR or the insulin receptor, is able to undergo sequential receptor-mediated transcytosis across the BBB, followed by receptor-mediated endocytosis into neurons. 18, 19 The PIL rapidly enters the nuclear compartment after endocytosis into the cell, as demonstrated by confocal microscopy. 20 In this study, the plasmid DNA was fluoresceinated with nick translation before encapsulation into PIL. The PIL was targeted to human U87 glioma cells using the murine 83-14 mAb to the human insulin receptor (HIR). The HIRmAb-targeted PIL was added to U87 cells and incubated for 3 or 24 h, followed by fixation and confocal microscopy. As shown in Figure  1C , the DNA is largely confined to the cytoplasmic compartment at 3 h, although DNA is detected within intranuclear vesicular structures at 3 h. By 24 h, virtually all of the intracellular DNA is found in the nuclear compartment (FIG. 1C) .
Global expression of transgene in rhesus monkey brain
The intravenous administration of PILs carrying an expression plasmid encoding bacterial ␤-galactosidase under the influence of the simian virus 40 (SV40) promoter to the adult rhesus monkey leads to global expres-sion of the trans-gene throughout the primate brain as demonstrated in Figure 1D . The PIL was targeted with a mAb to the HIR, and this mAb cross reacts with the Old World primate insulin receptor. 21 There is widespread expression of the transgene throughout the primate brain with a greater enrichment in gray matter relative to white matter (FIG. 1D) . Similar findings of global expression of a trans-gene throughout the entire brain after an intravenous injection of PILs has been demonstrated in mice using the rat 8D3mAb to the murine TfR, 18 and in rats using the murine OX26mAb to the rat TfR. 22 The targeting mAbs are species specific, and the 8D3mAb is not effective in rats, and the 83-14 HIRmAb is effective in humans and Old World primates such as rhesus monkeys, but is not effective in New World primates such as squirrel monkeys, and is not effective in rodents. The insulin receptor normally serves to deliver its endogenous ligand, insulin, to the nuclear compartment, and therefore, the insulin receptor is an ideal conduit for gene delivery. 23 Because of this nuclear targeting property of the insulin receptor, levels of gene expression in human cells or Old World primates can be 10-to 50-fold higher than comparable levels of gene expression in rodents, 19, 23 as demonstrated for the luciferase reporter gene (FIG. 1E) . The luciferase expression plasmid was encapsulated in TfRmAb-targeted PILs and injected into 19 E: Luciferase gene expression in the brain and other organs of the adult rhesus monkey (left panel) and adult rat (right panel) measured at 48 h after a single intravenous injection of the PIL carrying the plasmid DNA. Data are mean Ϯ SEM. The plasmid DNA encoding the luciferase gene used in either species is clone 790, which is driven by the SV40 promoter. 19 The PIL carrying the DNA was targeted to primate organs with an HIRmAb and to rat organs with a TfRmAb. 19 adult rats, and was separately encapsulated in HIRmAbtargeted PILs and injected into adult rhesus monkeys. 19 The animals were sacrificed 48 h after the intravenous injection for measurements of luciferase enzyme activity in brain and other organs. These studies show that luciferase expression is 50-fold higher in the primate as compared with rat. In addition to brain, the luciferase transgene is expressed in peripheral tissues such as liver or spleen, that also express the TfR or insulin receptor. However, this ectopic expression of the exogenous gene in nonbrain organs can be eliminated with the use tissuespecific gene promoters, as demonstrated for ␤-galactosidase gene expression in mice 18 or rhesus monkeys, 24 and discussed below in the case of TH gene therapy studies in rats.
TH GENE THERAPY OF EXPERIMENTAL PARKINSON'S DISEASE WITH PEGYLATED IMMUNOLIPOSOMES
Experimental PD was produced in adult rats with the intracerebral injection of a neurotoxin, 6-hydroxydopamine. 14, 25 The toxin was injected in the medial forebrain bundle of one side of the rat brain under stereotaxic guidance. Three weeks later, animals were tested with apomorphine, which causes aberrant rotation behavior in those animals with a successful biochemical lesion of the nigral-striatal tract. Before treatment of these animals with TH gene therapy, it is first necessary to synthesize TH expression plasmids. Because one goal of this work was to localize TH gene expression in the brain, two different expression plasmids were produced.
14, 25 The first plasmid, designated clone 877, encodes for the rat TH cDNA under the influence of the widely read SV40 promoter.
14 The second expression plasmid, designated clone 951, 25 is identical, except that the SV40 promoter is replaced with 2 kb of the 5Ј-flanking sequence (FS) of the human GFAP gene. The GFAP gene is expressed only in brain, and not in peripheral tissues. This was demonstrated in initial studies with a ␤-galactosidase reporter gene. When the ␤-galactosidase expression plasmid under the influence of the SV40 promoter was encapsulated in TfRmAb-targeted PILs and injected into rodents, the gene was expressed not only in brain, but TfR-rich peripheral organs such as liver or spleen. 22 However, when the ␤-galactosidase expression plasmid was under the influence of the GFAP promoter, the transgene was expressed only in brain, and ectopic gene expression in peripheral tissues was eliminated. 18 The biologic activity of clone 877 or clone 951 was initially evaluated in cell culture with either cultured RG2 rat glioma cells or cultured U87 human glioma cells. The TH gene is not expressed in cells unless there is local production of tetrahydrobiopterin, a critical TH cofactor. GTP-cylcohydrolase (GTPCH) is the rate-limiting enzyme in the pathway leading to the production of tetrahydrobiopterin, and cultured rat glioma cells 26 and cancer cell lines 27 produce the GTPCH enzyme, although glial cells in brain do not normally express the GTPCH gene. 28 Both clone 877 and clone 951 produce TH enzyme activity in either cultured rat glioma cells or cultured human U87 glioma cells (Table 1 ). There is a 5-to 8-fold higher level of TH gene expression in human cells, which are targeted with the HIRmAb, as opposed to TH gene expression in rat glioma cells, which are targeted with the TfRmAb. As noted above in the discussion of Figure 1E , PILs targeted with the insulin receptor normally yield a much higher level of gene expression than that obtained with PILs targeted with the TfRmAb.
19,23
The TfRmAb-targeted PILs carrying either clone 877 or clone 951 were injected intravenously into adult rats and TH enzyme activity was measured with a radioenzymatic assay at 3 days after a single intravenous injection in rats that had apomorphine-proven 6-hydroxydopamine lesions. The striatal TH was 98% depleted, as indicated by the very low TH level in the saline treated animals in the striatum ipsilateral to the 6-hydroxydopamine injection ( Table 2 ). The control is the contralateral striatum, which shows a more than 50-fold higher level of TH enzyme activity in the same rat brain (Table 2) . Both clone 877, the SV40 promoter driven plasmid, and clone 951, the GFAP promoter driven plasmid, were equally effective in restoring striatal TH enzyme activity in the ipsilateral striatum of the lesioned animals.
14,25 
Mean Ϯ SE (n ϭ 3 dishes per time point). PILs carrying either clone 877 or clone 951 are targeted to rat RG2 glioma cells with the TfRmAb and to human U87 glioma cells with the HIRmAb. 14, 25 Clone 877 also produced a 10-fold increase in hepatic TH because the SV40 promoter is expressed in this peripheral tissue. However, clone 951 caused no change in hepatic TH enzyme activity, and there was no ectopic expression of the TH gene in any of the peripheral tissues examined ( Table 2) . Administration of the TH gene did not result in any change in cortical TH enzyme activity. This is because the GTPCH gene is not expressed in cortex, 29 and local production of the tetrahydrobiopterin cofactor is an obligatory requirement for local TH gene expression. The biochemical assays of TH enzyme activity were corroborated with immunocytochemistry and measurements of immunoreactive TH (FIG. 2) . This study shows the results from six different rats, all of which had apomorphine proven 6-hydroxydopamine lesions on the right side of the brain. The three animals in panels A, B, and C of Figure 2 were treated with the TH gene encapsulated in PILs targeted with the TfRmAb. The three animals shown in D, E, and F of Figure 2 were treated with the TH gene encapsulated in PILs targeted with the mouse IgG2A isotype control, which had no receptor specificity. This immunocytochemical study shows complete normalization of striatal immunoreactive TH on the lesioned side with PIL gene therapy, *p Ͻ 0.01 difference from saline group (ANOVA with Bonferroni correction; n ϭ 4 rats per group). Rats were lesioned with intracerebral injections of 6-hydroxydopamine; 3 weeks after toxin injection the rats were tested for apomorphine-induced rotation behavior; those rats testing positively to apormorphine were selected for gene therapy, which was administered intravenously 4 weeks after toxin administration; all animals were euthanized 3 days after gene administration. Clones 877 and 951 are eukaryotic expression plasmids encoding the rat TH cDNA under the influence of either the widely expressed SV40 promoter, or the brain-specific GFAP promoter, respectively. 25 providing a receptor active targeting mAb is used. If an identical formulation is employed, except the TfRmAb targeting agent is replaced with a nontargeting agent, then no TH gene expression is observed. These results were corroborated by confocal microscopy using antibodies to TH, GFAP, the NeuN neuronal nuclear antigen, or the 200-kDa neurofilament protein (FIG. 3) . The fibers in the striate body ipsilateral to the lesion were immunoreactive for TH after intravenous administration of the TH gene encapsulated in TfRmAb targeted PILs (FIG.  3C) , but there was no expression of immunoreactive TH in these fibers when the PIL was targeted with the mouse IgG isotype control (FIG. 3B) . The expression of the immunoreactive TH in the striatum was confined to nerve endings as there was no colocalization of immunoreactive TH and astrocytic GFAP in the striate body of the gene therapy-treated animals (FIG. 3, G-I ). Confocal microscopy of the substantia nigra showed production of immunoreactive TH in nigral neuron cell bodies after a TH gene therapy (FIG. 3 , K and L). The normalization of striatal TH immunoreactive TH and striatal TH enzyme activity was correlated with the normalization of pharmacologic behavior in response to apomorphine. 14, 25 There was an 80% reduction in apomorphine induced rotation behavior in animals treated with intravenous TH gene therapy using PILs targeted with the TfRmAb (FIG.  4) . In contrast, in those lesioned animals that were treated with the TH gene encapsulated in PILs targeted with the nonspecific mouse IgG isotype control, there was no affect on apomorphine induced rotation behavior (FIG. 4) .
FIG. 2. Tyrosine hydroxylase immunocytochemistry of rat brain removed
Time-response and dose-response studies
The persistence of TH gene expression in the striate body ipsilateral to the 6-hydroxydopamine lesion was determined with measurements of striatal TH enzyme activity at 3, 6, and 9 days after a single intravenous injection of clone 877 plasmid DNA encapsulated in the TfRmAb-targeted PILs.
14 These data show striatal TH enzyme activity peaks at 3 days and decreases 50% by 6 days and approximately 90% by 9 days after a single intravenous injection (FIG. 5A) . A dose-response study was performed by measurement of TH enzyme activity in the striatum at 3 days after the intravenous injection of clone 877 plasmid DNA encapsulated in TfRmAb-targeted PILs at a dose of 1, 5, or 10 g plasmid DNA per rat.
14 There was no increase in striatal TH after the 1 g DNA/rat dose; there was an intermediate TH response after the intravenous injection of the 5 g DNA/rat dose, and there was complete normalization of striatal TH enzyme activity after the 10 g DNA/rat dose (FIG. 5B) . A per rat dose of 10 g of the 6.0 kb clone 877 plasmid DNA delivers 1.2 ϫ 10 9 plasmid molecules per gram of brain, as 0.07% of the injected PIL dose is delivered per gram of rat brain.
14 Assuming 10 8 cells per gram brain, the 10 g/rat dose delivers ϳ12 plasmid DNA molecules per brain cell. Conversely, only approximately one plasmid molecule per brain cell is delivered with 1 g/rat dose. These observations suggest that there is a very high efficiency of cell transfection with the PIL gene transfer technology, and that the cellular delivery of only 5-10 plasmid DNA molecules per cell is required for a full pharmacologic response from the gene therapy. After delivery of the TH gene across the BBB in the region of the substantia nigra in brain, the gene is incorporated into the neuronal nuclear compartments of the substantia nigra where the gene is transcribed and the TH protein is translated from the TH mRNA produced from the exogenous plasmid. The TH enzyme may then be transported to the striatum via one of two mechanisms. First, there is intense neuronal sprouting from the substantia nigra to the striatum that follows the intracerebral injection of 6-hydroxydopamine, such that the density of dopaminergic terminals in the striatum is returned nearly to normal, albeit these nerve fibers do not produce TH in the absence of gene therapy. 30, 31 Second, intracerebral fluorogold injection studies have shown that approximately 30% of nigral striatal neurons are intact after intracerebral injection of 6-hydroxydopamine. 32 Both GTPCH and the tetrahydrobiopterin cofactor levels in the striatum of the 6-hydroxydopamine-lesioned rat are still one third the concentrations in nonlesioned animal, 33 owing to striatal inputs from monoaminergic regions outside the substantia nigra.
The PIL gene transfer technology enables adult transgenics in 24-48 h and gives a picture similar to that obtained with conventional transgenics technology that requires pronuclear injections of genes into embryos. Transgenic mice expressing the human TH gene produce no TH mRNA in the cortex of these animals, 34 because there is no GTPCH gene expression or cofactor production in the cortex. Similarly, there is no change in TH gene expression in the cortex of adult rats administered the TH gene via the PIL gene transfer technology ( Table  2 ). The level of TH gene expression is tightly regulated within the brain so that supraphysiological levels of TH are not generated in the brain. Despite a 50-fold increase in TH mRNA in the substantia nigra of human TH transgenic mice, there is only a minor increase in TH protein in the striatum of these animals. 34 This finding is consistent with the observations made with the PIL gene transfer technology, where the level of TH enzyme activity is restored to normal but not supranormal levels by intravenous TH gene therapy (Table 2 ).
Brain gene expression driven by the GFAP promoter
The confocal studies show that the TH gene is expressed in neurons when the transgene is under the influence of GFAP promoter (FIG. 3) . Moreover, there is no detectable expression of the TH gene in astrocytes based on confocal microscopy and colabeling with antibodies to TH and GFAP (FIG. 3I) . This finding is consistent with the observation that astrocytes under normal conditions do not express the GTPCH gene. 28 The intracerebral injection of TH expression plasmids under the influence of the GFAP promoter can lead to astrocyte gene expression in brain when the expression plasmid is mixed with cationic liposomes. 35 However, cationic liposomes cause a brain injury reaction, 36 and the GTPCH gene is expressed in reactive astrocytes. 37 The finding of neuronal expression of the TH gene under the influence of the GFAP 5Ј-FS is consistent with earlier observations that the GFAP 5Ј-FS confers brain specificity of gene expression, but not astrocyte-specific gene expression. Astrocyte specific expression of the GFAP gene requires coordinated interactions between regulatory elements in both the 5Ј-FS and more distal parts of the gene, including the 3Ј-FS. 38, 39 Recent work in transgenic mouse models show that the 5Ј-FS of the GFAP gene enables widespread neuronal expression of transgene throughout the brain, 40 and these findings are consistent with the 14 observations of other studies that neurons produce transacting factors that interact with the 5Ј-FS of the GFAP gene.
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FUTURE DIRECTIONS
Gene expression in brain after administration of PILs is reversible and extrachromosomal. The plasmid DNA functions as an extrachromosomal episome, and persistence of expression of the transgene decays with time as the plasmid DNA is degraded. Southern blot studies show no chromosomal integration of the plasmid DNA. 22 The reversible nature of episomal-based gene therapy is considered desirable and advantageous over viral delivery systems that cause permanent integration into the host genome. With episomal-based gene therapy, the risk of chromosomal integration is nil, and the gene is given chronically at repeat occasions as with any other therapeutic. The interval of repeat administration is determined by the persistence of the transgene expression, which is a function of the structural elements engineered within the plasmid DNA. If the plasmid DNA incorporates chromosomal derived elements, then the expression plasmid can attract transacting factors within brain cells, which stabilize the plasmid against degradation by DNase I, which may produce more prolonged periods of gene expression. Gene therapy needs to move from the sole reliance on cDNA-based forms of therapeutic genes, to chromosomal-derived genes that include both the coding region and important 5Ј flanking sequence elements, and either intronic or 3Ј flanking sequence elements that contribute to stability of gene expression within the cell.
PILs can be administered to humans chronically as the only immunogenic component of the formulation is the antibody and the immunogenicity of the antibody can be eliminated with genetic engineering and the use of chimeric or humanized antibodies. A genetically engineered chimeric HIRmAb has been produced and has identical affinity for the HIR as does the original murine 83-14 HIRmAb. 42 PILs have been administered chronically by weekly intravenous administration to rats without any toxicologic effects and no inflammation within the brain. 43 Multiple genes can be delivered to brain with the PIL gene transfer technology, and an ideal form of gene therapy of PD would be aimed at the dual goals of TH replacement gene therapy and neuroprotection gene therapy.
